BR112016019929A2 - ligação de anticorpo biespecífico ao tlr2 humano e tlr4 humano - Google Patents

ligação de anticorpo biespecífico ao tlr2 humano e tlr4 humano

Info

Publication number
BR112016019929A2
BR112016019929A2 BR112016019929A BR112016019929A BR112016019929A2 BR 112016019929 A2 BR112016019929 A2 BR 112016019929A2 BR 112016019929 A BR112016019929 A BR 112016019929A BR 112016019929 A BR112016019929 A BR 112016019929A BR 112016019929 A2 BR112016019929 A2 BR 112016019929A2
Authority
BR
Brazil
Prior art keywords
human
amino acid
tlr2
tlr4
bispecific antibody
Prior art date
Application number
BR112016019929A
Other languages
English (en)
Inventor
Okuyama Chie
Suzuki Jotarou
Takasaki Jun
Aoyama Koji
Sato Masahito
Takeuchi Satoshi
SOGA Shinji
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112016019929A2 publication Critical patent/BR112016019929A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo ?ligação de anticorpo biespecífico ao tlr2 humano e tlr4 humano? problema fornecer um anticorpo biespecífico para prevenir ou tratar uma doença inflamatória imune atuando tanto no tlr2 humano quanto no tlr4 humano para inibir efeitos inflamatórios imunes mediados por tlr2 humano e tlr4 humano. meios para solução um anticorpo biespecífico para tlr2 humano e tlr4 humano, incluindo uma região variável de cadeia pesada de um anticorpo de anti-tlr2 humano que consiste da sequência de aminoácidos de números de aminoácidos de 1 a 120 de seq id no: 4; uma região variável de cadeia leve de um anticorpo de anti-tlr2 humano que consiste da sequência de aminoácidos de números de aminoácidos de 1 a 113 de seq id no: 6; uma região variável de cadeia pesada de um anticorpo de anti-tlr4 humano que consiste da sequência de aminoácidos de números de aminoácidos de 491 a 609 de seq id no: 4; e uma região variável de cadeia leve de um anticorpo de anti-tlr4 humano que consiste da sequência de aminoácidos de números de aminoácidos de 625 a 732 de seq id no: 4, é fornecido.
BR112016019929A 2014-02-28 2015-02-27 ligação de anticorpo biespecífico ao tlr2 humano e tlr4 humano BR112016019929A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014038438 2014-02-28
PCT/JP2015/055860 WO2015129858A1 (ja) 2014-02-28 2015-02-27 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体

Publications (1)

Publication Number Publication Date
BR112016019929A2 true BR112016019929A2 (pt) 2017-10-17

Family

ID=54009171

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019929A BR112016019929A2 (pt) 2014-02-28 2015-02-27 ligação de anticorpo biespecífico ao tlr2 humano e tlr4 humano

Country Status (14)

Country Link
US (1) US10253105B2 (pt)
EP (1) EP3112462B1 (pt)
JP (1) JP6579097B2 (pt)
KR (1) KR20160125965A (pt)
CN (1) CN106062193B (pt)
BR (1) BR112016019929A2 (pt)
CA (1) CA2941014A1 (pt)
ES (1) ES2709996T3 (pt)
MX (1) MX2016011228A (pt)
PL (1) PL3112462T3 (pt)
PT (1) PT3112462T (pt)
RU (1) RU2016134913A (pt)
TR (1) TR201901045T4 (pt)
WO (1) WO2015129858A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048971A1 (fr) * 2016-03-15 2017-09-22 Univ Rabelais Francois Constructions peptidiques bispecifiques et leur utilisation dans le traitement de maladies notamment imflammatoires

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
JP4263953B2 (ja) 2003-06-23 2009-05-13 三洋電機株式会社 半導体装置及びその製造方法
JP3810388B2 (ja) 2003-07-14 2006-08-16 株式会社中央精機 両頭側面フライス盤
WO2005019431A2 (en) 2003-08-20 2005-03-03 University Of Massachusetts Selective inhibition of toll-like receptor-2
US8623353B1 (en) 2003-09-23 2014-01-07 Technische Universitat Munchen TLR2 antagonistic antibody and use thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
MXPA06000176A (es) * 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
AU2004311541B2 (en) 2003-12-10 2011-06-30 Novimmune Sa Neutralizing antibodies and methods of use thereof
US8029794B2 (en) * 2004-12-10 2011-10-04 Novimmune S.A. Combining therapies targeting multiple toll-like receptors
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α４β７雜二聚體專一性拮抗抗體
WO2010115553A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2780372B1 (en) * 2011-11-17 2019-01-02 Jung, Gundram Bi-specific antibodies for medical use
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
CA2869048C (en) 2012-03-29 2023-10-17 Novimmune S.A. Anti-tlr4 antibodies and uses thereof

Also Published As

Publication number Publication date
CA2941014A1 (en) 2015-09-03
EP3112462A4 (en) 2017-11-01
PT3112462T (pt) 2019-02-08
KR20160125965A (ko) 2016-11-01
EP3112462A1 (en) 2017-01-04
EP3112462B1 (en) 2018-12-05
JP6579097B2 (ja) 2019-09-25
WO2015129858A1 (ja) 2015-09-03
TR201901045T4 (tr) 2019-02-21
US20160355602A1 (en) 2016-12-08
MX2016011228A (es) 2016-11-30
ES2709996T3 (es) 2019-04-22
PL3112462T3 (pl) 2019-06-28
JPWO2015129858A1 (ja) 2017-03-30
CN106062193B (zh) 2020-08-25
CN106062193A (zh) 2016-10-26
RU2016134913A (ru) 2018-03-30
US10253105B2 (en) 2019-04-09

Similar Documents

Publication Publication Date Title
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
BR112019001138A2 (pt) proteínas biespecíficas e métodos para preparar as mesmas
ECSP17083788A (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
CO2018005680A2 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
BR112018015485A2 (pt) imunoglobulina fabs-in-tandem e usos da mesma
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
MX2019002867A (es) Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
CL2019003419A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales.
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
CL2017001255A1 (es) Composición de rehidratación oral y los métodos de la misma
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
EA201890097A1 (ru) Индукция регуляторных т-клеток lamina propria
MX2018015410A (es) Esteres de oxaborol y sus usos.
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
MX2016014144A (es) Composiciones de proteina concentrada y metodos para su elaboracion y uso.
BR112018075303A2 (pt) resumo método para tratar uma doença ou condição inflamatória, e método de redução ou inibição de uma resposta imune
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
CL2020000329A1 (es) Sistemas y métodos para el control de la enfermedad de necrosis hepatopancreática aguda.
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]